Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polymolecular marker composition used for lung cancer diagnosis

A protein marker and lung cancer technology, applied in the field of disease diagnosis, can solve the problems of increased difficulty in lung cancer diagnosis and screening, increased difficulty of diagnosis, and low early cancer diagnosis rate

Inactive Publication Date: 2017-05-17
金式麦生物科技(杭州)有限公司
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although the above tumor markers have been applied in the clinical screening of lung cancer, the sensitivity of these biomarkers is about 40-60%, especially the diagnosis rate of early cancer is very low
The heterogeneity of lung tumors makes the diagnosis and screening of lung cancer more difficult, and when the tumor develops to different stages and different pathological stages, tumor markers will also change accordingly, which also increases the difficulty of diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymolecular marker composition used for lung cancer diagnosis
  • Polymolecular marker composition used for lung cancer diagnosis
  • Polymolecular marker composition used for lung cancer diagnosis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0084] (1) Preparation of liquid phase chip (each protein is coated with corresponding microspheres, the preparation method is the same)

[0085] 1) Take the microsphere suspension (magnetic microspheres, bio-rad), vortex and sonicate for about 20s respectively, take 200ul (about 2.5×10 6 microspheres) in a clean centrifuge tube (USA, Axygen), marked with the microsphere model and protein name;

[0086] 2) 14000g, room temperature (about 25°C), 4min; carefully suck off the supernatant, and a small amount of supernatant can be left to reduce loss;

[0087] 3) Add 100ul ddH 2 O, vortex and sonicate for about 20s respectively;

[0088] 4) 14000g, room temperature, 4min; carefully suck off the supernatant, in order to reduce the loss, a small amount of supernatant can be left, add 160ul pH6.2, 0.1M NaH 2 PO 4 , respectively vortex and sonicate for about 20s;

[0089] 5) Quickly add 20ul S-NHS, vortex and mix;

[0090] 6) Quickly add 20ul EDC, vortex and sonicate for about 20...

Embodiment 1

[0138] Example 1, screening of markers

[0139] The inventor collected 804 cases of patients in total, including 543 cases in the test group and 261 cases in the verification group. There were 575 cases in the healthy group, including 301 cases in the test group and 274 cases in the verification group. In addition, 70 patients with other benign lung diseases and 80 patients with small pulmonary nodules were included.

[0140] Statistical results show that there is no significant statistical difference in gender, smoking status, age and other factors between the healthy group and the experimental case (test group, verification group) group.

[0141] The clinical case characteristics of the subjects are summarized in Table 3.

[0142] table 3

[0143]

[0144] P value χ 2 test.

Embodiment 2

[0145] Example 2. Screening and validation of lung cancer-related molecular markers

[0146] In the present invention, the screening process of lung cancer markers is as follows: figure 1 .

[0147] The purpose of this example is to screen out molecular markers that can distinguish healthy people from lung cancer patients. A large-scale comparison of proteins expressed in serum samples of lung cancer patients with those of healthy individuals is expected to screen out lung cancer-related molecular markers.

[0148] After a large sample size analysis and screening, as a result, the inventors screened out a total of 8 proteins, which are highly expressed in lung cancer patients, and can better distinguish healthy people from lung cancer patients, including: C-reactive protein (CRP), prolactin Prolactin, hepatocyte growth factor (HGF), CEA, WIPS1, Cyfra21-1, CA125, BORIS (P image 3 .

[0149] Therefore, the present inventors found 8 effective molecular markers in total.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a polymolecular marker composition used for lung cancer diagnosis. The invention discloses a group of lung cancer combined markers, including hepatocyte growth factor, C-reactive protein, prolactin, Wnt induced signal path protein 1 (WISP1), imprinting site binding factor (BORIS), CA125, cytokeratin 19 segment and carcino-embryonic antigen. In serum of lung cancer patients, the expression of these proteins is obviously higher than that of non-cancer patients. These markers are combined to be applied to clinical diagnosis, so that the accuracy of lung cancer diagnosis can be obviously improved, and early-stage patients suffering from lung cancer can be detected.

Description

technical field [0001] The invention belongs to the technical field of disease diagnosis, and more specifically, the invention relates to a combination of multi-molecular markers for lung cancer diagnosis. Background technique [0002] Lung cancer has been the leading cause of cancer-related death in the global population for many years. According to survey results, in 2015, 73,300 cases of lung cancer were diagnosed in China, and 610,200 people died of lung cancer. The 5-year survival rate of lung cancer is about 17%, and the overall survival rate has not improved significantly in recent years. Due to the lack of effective methods for early diagnosis of lung cancer, more than half of the patients are diagnosed at an advanced stage, thus losing the chance of resection. [0003] Clinically, the detection of lung cancer still relies on CT, MR, PET and other imaging detection equipment, but in fact these imaging methods can only detect tumors larger than 1-2cm, and it usually ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/74G01N33/68G01N33/577G01N33/574
CPCG01N33/574G01N33/57423G01N33/57473G01N33/57484G01N33/577G01N33/68G01N33/74
Inventor 王孝举马胜林王闻哲张衍梅汪成发
Owner 金式麦生物科技(杭州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com